Xu J - Search Results

1

High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer.

Mei J, Cai Y, Zhu H, Jiang Y, Fu Z, Xu J, Chen L, Yang K, Zhao J, Song C, Zhang Y, Mao W, Yin Y. Mei J, et al. Among authors: xu j. NPJ Breast Cancer. 2024 Jan 27;10(1):11. doi: 10.1038/s41523-024-00618-6. NPJ Breast Cancer. 2024. PMID: 38280882 Free PMC article.

2

NY-ESO-1 expression in solid tumors predicts prognosis: A systematic review and meta-analysis.

Wang H, Chen D, Wang R, Quan W, Xia D, Mei J, Xu J, Liu C. Wang H, et al. Among authors: xu j. Medicine (Baltimore). 2019 Nov;98(48):e17990. doi: 10.1097/MD.0000000000017990. Medicine (Baltimore). 2019. PMID: 31770209 Free PMC article.

3

A comparability study of natural and deglycosylated PD-L1 levels in lung cancer: evidence from immunohistochemical analysis.

Mei J, Xu J, Yang X, Gu D, Zhou W, Wang H, Liu C. Mei J, et al. Among authors: xu j. Mol Cancer. 2021 Jan 7;20(1):11. doi: 10.1186/s12943-020-01304-4. Mol Cancer. 2021. PMID: 33413365 Free PMC article.

4

Wnt5a: A promising therapeutic target in ovarian cancer.

Zhou W, Mei J, Gu D, Xu J, Wang R, Wang H, Liu C. Zhou W, et al. Among authors: xu j. Pathol Res Pract. 2021 Mar;219:153348. doi: 10.1016/j.prp.2021.153348. Epub 2021 Jan 27. Pathol Res Pract. 2021. PMID: 33540373 Review.

5

Removal of N-Linked Glycosylation Enhances PD-L1 Detection in Colon Cancer: Validation Research Based on Immunohistochemistry Analysis.

Xu J, Yang X, Mao Y, Mei J, Wang H, Ding J, Hua D. Xu J, et al. Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211019442. doi: 10.1177/15330338211019442. Technol Cancer Res Treat. 2021. PMID: 34060360 Free PMC article.

6

Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer.

Xu J, Yang X, Pan J, Fan H, Mei J, Hua D. Xu J, et al. J Oncol. 2022 Feb 22;2022:3224373. doi: 10.1155/2022/3224373. eCollection 2022. J Oncol. 2022. PMID: 35242187 Free PMC article.

7

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC.

Mei J, Jiang G, Chen Y, Xu Y, Wan Y, Chen R, Liu F, Mao W, Zheng M, Xu J. Mei J, et al. Among authors: xu y, xu j. BMC Cancer. 2022 Jul 6;22(1):738. doi: 10.1186/s12885-022-09840-6. BMC Cancer. 2022. PMID: 35794593 Free PMC article.

8

Case Report: Successful Immunotherapy Improved the Prognosis of the Unfavorable Subset of Cancer of Unknown Primary.

Mei J, Wang H, Fan H, Ding J, Xu J. Mei J, et al. Among authors: xu j. Front Immunol. 2022 Jun 22;13:900119. doi: 10.3389/fimmu.2022.900119. eCollection 2022. Front Immunol. 2022. PMID: 35812375 Free PMC article.

9

ZEB1: Catalyst of immune escape during tumor metastasis.

Lu J, Fei F, Wu C, Mei J, Xu J, Lu P. Lu J, et al. Among authors: xu j. Biomed Pharmacother. 2022 Sep;153:113490. doi: 10.1016/j.biopha.2022.113490. Epub 2022 Aug 1. Biomed Pharmacother. 2022. PMID: 36076506 Free article. Review.

10

The Clinical Significance of Deglycosylated PD-L1 Level Detection Using 28-8 Monoclonal Antibody in Lung Adenocarcinoma.

Wang H, Gu D, Chen D, Mei J, Yang X, Ding J, Xu J, Wang M, Liu C, Hua D. Wang H, et al. Among authors: xu j. Int J Gen Med. 2022 Sep 19;15:7383-7393. doi: 10.2147/IJGM.S381530. eCollection 2022. Int J Gen Med. 2022. PMID: 36164284 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66,886 results

Search Page

Filters